Renal safety and biochemical changes for 2 years after switching to tenofovir alafenamide from long-term other nucleotide analog treatment in patients with chronic hepatitis B.

Tetsuya HosakaFumitaka SuzukiMasahiro KobayashiShunichirou Fujiyama Yusuke Kawamura Hitomi Sezaki Norio AkutaYoshiyuki SuzukiSatoshi SaitohYasuji AraseKenji IkedaMariko KobayashiHiromitsu Kumada

Published in: Hepatology research : the official journal of the Japan Society of Hepatology (2021)

Switching from TDF or ADV to TAF resulted in favorable renal safety for 2 years. In CKD stage 3a-4 subgroup, eGFR after TAF was recovered in the first 12 weeks and subsequently stabilized.

Keyphrases

small cell lung cancer
hepatitis b virus
chronic kidney disease
epidermal growth factor receptor
tyrosine kinase
antiretroviral therapy
gestational age
liver fibrosis
smoking cessation
preterm birth